Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salanersen - Biogen/Ionis Pharmaceuticals

Next Previous
Drug Profile

Salanersen - Biogen/Ionis Pharmaceuticals

Alternative Names: BIIB-115; ION-306

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Biogen; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Gene silencing; Survival of motor neuron 2 protein expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Spinal muscular atrophy

Most Recent Events

  • 11 Aug 2026 Phase-III clinical trials in Spinal muscular atrophy (In infants, In neonates, Treatment-experienced) in USA (Intrathecal) (NCT07444450)
  • 04 Jun 2026 Biogen plans a phase III STELLAR-2 trial for Spinal muscular atrophy (Treatment experienced, In neonates, In infants) in unknown location (Intrathecal, Injection) in June 2026 (NCT07444450)
  • 04 Jun 2026 Salanersen - Biogen/Ionis Pharmaceuticals receives Breakthrough Therapy status for Spinal muscular atrophy in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top